Insulin Glargine: A Reevaluation of Rodent Carcinogenicity Findings

Stammberger, Ingo; Essermeant, Luc

doi:10.1177/1091581811431111

Cited by 19 publications

(12 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2002, an animal study [34] that lasted for 2 years demonstrated that insulin glargine did not have a systemic cancerigenic potential in rats and mice. A recent study [35] by the same investigators reevaluating the carcinogenicity potential of insulin glargine indicated that cancer risk was found to be no greater for animals treated with insulin glargine than for the control-treated animals. They considered that insulin glargine was not likely to pose a cancer risk in humans and the findings needed to be confirmed by ongoing clinical studies.…”

Section: Discussionmentioning

confidence: 99%

Insulin Glargine and Cancer Risk in Patients with Diabetes: A Meta-Analysis

et al. 2012

View full text Add to dashboard Cite

AimThe role of insulin glargine as a risk factor for cancer is controversial in human studies. The aim of this meta-analysis was to evaluate the relationship between insulin glargine and cancer incidence.MethodsAll observational studies and randomized controlled trials evaluating the relationship of insulin glargine and cancer risk were identified in PubMed, Embase, Web of Science, Cochrane Library and the Chinese Biomedical Medical Literature Database, through March 2012. Odds ratios (ORs) with corresponding 95% confidence interval (CI) were calculated with a random-effects model. Confidence in the estimates of the obtained effects (quality of evidence) was assessed by using the Grading of Recommendations Assessment, Development, and Evaluation approach.ResultsA total of 11 studies including 448,928 study subjects and 19,128 cancer patients were finally identified for the meta-analysis. Insulin glargine use was associated with a lower odds of cancer compared with non-glargine insulin use (OR 0.81, 95% CI 0.68 to 0.98, P = 0.03; very low-quality evidence). Glargine did not increase the odds of breast cancer (OR 0.99, 95% CI 0.68 to 1.46, P = 0.966; very low-quality evidence). Compared with non-glargine insulin, no significant association was found between insulin glargine and prostate cancer, pancreatic cancer and respiratory tract cancer. Insulin glargine use was associated with lower odds of other site-specific cancer. Conclusions Results from the meta-analysis don't support the link between insulin glargine and an increased risk of cancer and the confidence in the estimates of the effects is very low. Further studies are needed to examine the relation between insulin glargine and cancer risk, especially breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Insulin Glargine and Cancer Risk in Patients with Diabetes: A Meta-Analysis

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Moreover, study conducted by Colmers et al revealed increased risk of pancreatic and prostate cancers in glargine users. On the contrary, several studies found that glargine did not increase carcinogenic risk [132,133]. It is also suggested that there is neutral relationship between glargine and overall/cancer-specific outcomes [134].…”

Section: Exogenous Insulin ▼mentioning

confidence: 99%

Diabetes and Cancer: a Review of Current Knowledge

Wojciechowska

Krajewski

Bolanowski³

et al. 2016

Exp Clin Endocrinol Diabetes

175

117

View full text Add to dashboard Cite

Diabetes mellitus (DM), one of the most common life-threatening illnesses worldwide, is a group of metabolic diseases, characterized by sustained hyperglycemia. The global prevalence of diabetes mellitus among adults reached 387 millions in 2014 and is still rising. It is suggested there is a strong association between diabetes mellitus (especially type 2 diabetes mellitus) and carcinogenesis. The possible biological links between diabetes mellitus and cancer comprise hyperinsulinemia, hyperglycemia and fat-induced chronic inflammation. Although, the strongest association refers to pancreas and liver, there are many other organs involved in carcinogenesis in diabetic patients including breast, endometrium, bladder and kidney. Recent studies suggest that there is also association between cancer incidence and anti-diabetic medications. It was observed that some medications decrease the risk of carcinogenesis and some increase that risk. The majority of studies concern metformin, a drug of choice in type 2 diabetes mellitus, and its anti-neoplastic and tumor-suppressing activity. The positive effect of metformin was found in numerous researches investigating breast, pancreas, liver, colon, ovaries and prostate tumors. Because a variety of studies have suggested that diabetes mellitus and cancer are frequently coexisting diseases, recently published studies try to explain the influence of diabetes mellitus and anti-diabetic medications on carcinogenesis in different organs. We present the review of the latest studies investigating the association between both diabetes mellitus and anti-diabetic medications and cancer incidence and prognosis. Particularly we highlight the problem of concomitant head and neck cancers in diabetics, rarely analysed and often omitted in studies.

show abstract

“…Conversely, it is important to note that many studies found that glargine did not increase carcinogenic risk, and a neutral link between glargine and overall/cancerspecific outcomes was also suggested [108][109][110].…”

Section: Insulin and Insulin Analogsmentioning

confidence: 99%

Linking type 2 diabetes and gynecological cancer: an introductory overview

Anastasi

Filardi

Tartaglione

et al. 2018

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Type 2 diabetes (T2D) is a chronic disease with a growing prevalence and a leading cause of death in many countries. Several epidemiological studies observed an association between T2D and increased risk of many types of cancer, such as gynecologic neoplasms (endometrial, cervical, ovarian and vulvar cancer). Insulin resistance, chronic inflammation and high free ovarian steroid hormones are considered the possible mechanisms behind this complex relationship. A higher risk of endometrial cancer was observed in T2D, even though this association largely attenuated after adjusting for obesity. A clear relationship between the incidence of cervical cancer (CC) and T2D has still not be determined; however T2D might have an impact on prognosis in patients with CC. To date, studies on the association between T2D and ovarian cancer (OC) are limited. The effect of pre-existing diabetes on cancer-specific mortality has been evaluated in several studies, with less clear results. Other epidemiological and experimental studies focused on the potential role of diabetes medications, mainly metformin, in cancer development in women. The correct understanding of the link between T2D and gynecologic cancer risk and mortality is currently imperative to possibly modify screening and diagnostic-therapeutic protocols in the future.

show abstract

Insulin Glargine: A Reevaluation of Rodent Carcinogenicity Findings

Cited by 19 publications

References 15 publications

Insulin Glargine and Cancer Risk in Patients with Diabetes: A Meta-Analysis

Insulin Glargine and Cancer Risk in Patients with Diabetes: A Meta-Analysis

Diabetes and Cancer: a Review of Current Knowledge

Linking type 2 diabetes and gynecological cancer: an introductory overview

Contact Info

Product

Resources

About